The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
3-(2,4-dichlorophenyl)-N1-hydroxy-N5-(3-hydroxybenzyl)pentanediamide ID: ALA4872321
PubChem CID: 164619051
Max Phase: Preclinical
Molecular Formula: C18H18Cl2N2O4
Molecular Weight: 397.26
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: O=C(CC(CC(=O)NCc1cccc(O)c1)c1ccc(Cl)cc1Cl)NO
Standard InChI: InChI=1S/C18H18Cl2N2O4/c19-13-4-5-15(16(20)9-13)12(8-18(25)22-26)7-17(24)21-10-11-2-1-3-14(23)6-11/h1-6,9,12,23,26H,7-8,10H2,(H,21,24)(H,22,25)
Standard InChI Key: GUYBIDSOBSYRIO-UHFFFAOYSA-N
Molfile:
RDKit 2D
26 27 0 0 0 0 0 0 0 0999 V2000
35.2630 -19.3691 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.9749 -18.9605 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.6867 -19.3691 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.3985 -18.9605 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
38.1104 -19.3691 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.8181 -18.9605 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.5246 -19.3733 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.2318 -18.9654 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.2318 -18.1473 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.5196 -17.7389 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.8181 -18.1492 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.6867 -20.1904 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
34.5512 -18.9605 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.5512 -18.1381 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.8451 -17.7255 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.1323 -18.1382 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.1323 -18.9638 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.8465 -19.3686 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.4241 -17.7265 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
35.2693 -17.7277 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
35.2630 -20.1904 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.5512 -20.6031 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.5512 -21.4244 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
33.8394 -21.8330 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
33.8394 -20.1904 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
39.5161 -16.9217 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 1 0
3 4 1 0
4 5 1 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 10 1 0
10 11 2 0
11 6 1 0
3 12 2 0
1 13 1 0
13 14 2 0
14 15 1 0
15 16 2 0
16 17 1 0
17 18 2 0
18 13 1 0
16 19 1 0
14 20 1 0
1 21 1 0
21 22 1 0
22 23 1 0
23 24 1 0
22 25 2 0
10 26 1 0
M END Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 397.26Molecular Weight (Monoisotopic): 396.0644AlogP: 3.38#Rotatable Bonds: 7Polar Surface Area: 98.66Molecular Species: NEUTRALHBA: 4HBD: 4#RO5 Violations: ┄HBA (Lipinski): 6HBD (Lipinski): 4#RO5 Violations (Lipinski): ┄CX Acidic pKa: 8.79CX Basic pKa: ┄CX LogP: 2.70CX LogD: 2.68Aromatic Rings: 2Heavy Atoms: 26QED Weighted: 0.43Np Likeness Score: -0.56
References 1. Turner LD, Nielsen AL, Lin L, Campedelli AJ, Silvaggi NR, Chen JS, Wakefield AE, Allen KN, Janda KD.. (2021) Use of Crystallography and Molecular Modeling for the Inhibition of the Botulinum Neurotoxin A Protease., 12 (8.0): [PMID:34413962 ] [10.1021/acsmedchemlett.1c00325 ]